8月18日 - ** 券商瑞银将医疗保健集团 CVS Health CVS.N 的评级从 "中性 "上调至 "买入"，将目标价从 67 美元上调至 79 美元。
** 与该股上次收盘价相比，新的PT上涨了13.2%。
** CVS 股价盘前上涨 2.2%，报 70.1 美元
** 瑞银称 CVS 对其医疗保险优势计划管理得当，使该经纪公司对其未来表现更有信心
** 瑞银认为 CVS 将在 2026 年底之前减少债务，从而允许更多的股票回购和进一步的盈利增长
** 瑞银表示，预计近期内药品定价规则或星级评级不会 出现重大负面变化
** 截至上次收盘，CVS 股价年累计上涨 52.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.